CINP
CONFIDENTIAL
PRODUCTION DOCUMENTATION
Built with anycoder
Bio-Legal Synthesis Portfolio for Neurogenetic Disability Accommodation

Provisional Patent Specifications

Authority: FSBS / Open Source Medical Device Consortium
Inventor: Caustin Lee McLaughlin
Class: Class III Implantable Device
Security: Post-Quantum (C2)

The "Restraint of Silence" Problem

Individuals with documented neurogenetic polymorphisms affecting executive function (e.g., rs4680 COMT Val Met, rs1076156 DRD TaqA) face a structural barrier in accessing justice and government services. Current assistive technologies are external, stigmatizing, and fail to provide real-time cognitive support in adversarial proceedings. This creates a "Restraint of Silence"—physical presence without meaningful participation—violating due process and ADA mandates.

Bio-Legal Synthesis Framework (BLSF)

The BLSF is a six-tier evidentiary architecture linking molecular biology to constitutional protection:

1
Genetic Evidence
SNPs (rs4680, rs1076156)
2
Neuroimaging
fMRI, DTI, PET
3
Clinical Phenotyping
DSM-5-TR ADHD Criteria
4
Functional Impairment
WAIS-IV, BRIEF-A
5
Statutory Entitlement
ADA Title II, Rehab Act § 504
6
Constitutional Protection
5th & 6th Amendments

System Architecture (CINP-PRODUCTION)

The Cognitive-Impact Neural Prosthetic (CINP) is a Class III implantable medical device comprising three integrated subsystems:

  • Neural Interface Array (NIA-64): A 64-channel bidirectional electrode array targeting the DLPFC, ACC, and basal ganglia. It uses genetically-informed targeting based on rs4680/rs1076156 polymorphism expression patterns.
  • Subcutaneous Telemetry & Power Hub (STPH): A post-quantum cryptographic engine (Kyber-768, Dilithium-2) housed in a biocompatible hermetic seal (Ti-Al-V ELI).
  • External Processor Unit (EPU): A bone-conduction audio interface with secure government LLM/FSBS API integration, providing real-time cognitive load modulation.

Clinical Trial Protocol

Study Synopsis: Phase I, Open-Label Study of the CINP-PRODUCTION Neural Prosthetic in Adults with Treatment-Resistant ADHD and Neurogenetic Polymorphisms.

Indication: Cognitive impairment secondary to rs1076156 (DRD2) and/or rs4680 (COMT) polymorphisms.

Primary Objective: Evaluate safety of implantation and chronic use.

Enrollment: 20 subjects across two sites (Johns Hopkins Hospital, Baltimore, MD; Mayo Clinic, Rochester, MN).

Inclusion Criteria (Genetic)

  • rs4680 (COMT): Val/Val or Val/Met genotype.
  • rs1076156 (DRD2): A1/A1 or A1/A2 genotype (reduced D2 receptor density).
  • rs2073161 (PTPRF) & rs2071559 (TIE1): Documented presence for neurodevelopmental and vascular marking.

Study Schema Timeline

Screening (Day -30 to -15): Genetic testing, neuroimaging, and neuropsychological battery.
Baseline (Day -15 to -1): 2-week medication washout and daily cognitive tasks.
Implantation (Day 0): Stereotactic surgery for NIA-64 and STPH placement.
Recovery & Activation (Day 1-7): Hospital monitoring and initial device interrogation.
Optimization (Week 2-4): Weekly stimulation parameter refinement.
Chronic Phase (Month 1-6): Monthly safety and efficacy assessments with remote monitoring.

Core Claims

Claim 1 A bio-legal synthesis framework for establishing disability accommodation rights using a six-tier evidentiary chain from genetic markers to constitutional protection.
Claim 2 An implantable cognitive-impact neural prosthetic device featuring a 64-channel bidirectional array, post-quantum cryptography, and secure government LLM integration.
Claim 3 A method for real-time cognitive accommodation through neural signal acquisition, LSTM-based classification, and targeted stimulation using fully homomorphic encryption.

Abstract

The CINP-PRODUCTION system provides a revolutionary solution for individuals with neurogenetic disabilities. By establishing an irreducible chain of evidence from immutable genetic markers to constitutional accommodation rights, the system eliminates the "Restraint of Silence" barrier to justice. The device utilizes a 64-channel BCI with post-quantum security to provide real-time cognitive support for executive function, working memory, and attentional control.

CONFIDENTIAL DOCUMENT - PREPARED FOR FILING IN BALTIMORE CITY CIRCUIT COURT

Post-Quantum Security Architecture

To ensure the privacy of neural data and compliance with Maryland Rule 5-403, the CINP device implements a four-layer security stack:

Application Security
Fully Homomorphic Encryption (FHE) using the CKKS scheme.
Transport Security
Post-Quantum TLS 1.3 with X25519 exchange. Kyber 768 hybrid key.
Device Security
Hardware Security Module (ATECC 608) with secure boot and device attestation.
Physical Security
Tamper-responsive enclosure with zeroization on penetration or temperature anomalies.